Compare JPMorgan Chase & Co (JPM) vs Pfizer Inc (PFE) Price & Performance

JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, near its pivot point of $359. The stock shows a bullish technical trend with moving averages supporting upside. Recent earnings beat expectations in Q1 and Q2 2026, with Q1 EPS of $5.94 versus $5.47 expected, though Q4 2025 missed. Revenue grew to $181.85B in 2025, and net income margin stands at 33.38%. A $1.50 dividend is scheduled for payment on July 31, 2026.

JPMorgan's outlook remains positive with analyst consensus at 'Moderate Buy' and a $374.18 price target, offering ~4% upside. Strong ROE of 18.43% and institutional accumulation highlight confidence. Risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI, as noted in recent news. The stock's valuation at P/E 15.42 is reasonable relative to earnings growth potential.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.